Reset filters
7 April 2025

Pulmonary artery hypertension (PAH) is a fatal disease associated with high mortality, especially in countries with limited health resources in terms of lack of access to diagnostic and therapeutic evaluations. Therefore, it is necessary to discover inexpensive and available serum biomarkers for examining patients.

Pulmonary Circulation
2 April 2025

Pulmonary arterial endothelial and smooth muscle cell homeostasis is regulated through the bone morphogenetic protein (BMP) and transforming growth factor beta (TGF-β) receptor pathways. Pathway imbalance results in pulmonary hypertension (PH). Each pathway has ligands and modulators influencing this balance. How these pathways differ in pediatric PH patients is unknown.

Pulmonary Circulation
2 April 2025

Pulmonary hypertension (PH) is a rare, complex disease affecting both children and adults. Efforts to provide health education are imperative as health literacy impacts patient and caregiver capacity to acquire, process, and understand health information and make informed health decisions. 

Pulmonary Circulation
31 March 2025

Pulmonary arterial hypertension (PAH) is a disease that can eventually progress to right ventricular failure. Heart rate variability (HRV), including standard deviation of R-to-R intervals (SDNN), has been associated with increased mortality across different populations. The purpose of this study was to examine the association between HRV and disease severity in PAH.

Pulmonary Circulation
20 March 2025

159 meeting abstracts from PVRI 2025 Rio.

Pulmonary Circulation